Amgen Inc. announced April 10 that it plans to acquire KAI Pharmaceuticals Inc. The Big Biotech paid $315 million in cash for the South San Francisco, Calif., biotech with plans to move its lead compound into late-stage as soon as possible.
KAI is currently developing KAI-4169, a peptide agonist of the calcium sensing receptor being developed for treatment of secondary hyperparathyroidism...